-
International Journal of Nanomedicine
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Polydisulfide Gd(III) chelates as biodegradable macromolecular magnetic resonance imaging contrast agents
(2577) Views (516) Full article downloads
Authors: Zheng-Rong Lu, Aaron M Mohs, Yuda Zong, Yi Feng
Published Date January 2006
Volume 2006:1(1) Pages 31 - 40
DOI: http://dx.doi.org/10.2147/IJN.S
Zheng-Rong Lu, Aaron M Mohs, Yuda Zong, Yi Feng Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, UT, USA
Abstract: Macromolecular gadolinium (Gd)(III) complexes have a prolonged blood circulation time and can preferentially accumulate in solid tumors, depending on the tumor blood vessel hyperpermeability, resulting in superior contrast enhancement in magnetic resonance (MR) cardiovascular imaging and cancer imaging as shown in animal models. Unfortunately, safety concerns related to these agents’ slow elimination from the body impede their clinical development. Polydisulfide Gd(III) complexes have been designed and developed as biodegradable macromolecular magnetic resonance imaging (MRI) contrast agents to facilitate the clearance of Gd(III) complexes from the body after MRI examinations. These novel agents can act as macromolecular contrast agents for in vivo imaging and excrete rapidly as lowmolecular-weight agents. The rationale and recent development of the novel biodegradable contrast agents are reviewed here. Polydisulfide Gd(III) complexes have relatively long blood circulation time and gradually degrade into small Gd(III) complexes, which are rapidly excreted via renal filtration. These agents result in effective and prolonged in vivo contrast enhancement in the blood pool and tumor tissue in animal models, yet demonstrate minimal Gd(III) tissue retention as the clinically used low-molecular-weight agents. Structural modification of the agents can readily alter the contrast-enhancement kinetics. Polydisulfide Gd(III) complexes are promising for further clinical development as safe, effective, biodegradable macromolecular MRI contrast agents for cardiovascular and cancer imaging, and for evaluation of therapeutic response.
Keywords: biodegradable, contrast agents, gadolinium, MRI, polydisulfide
Readers of this article also read:
Enhanced endothelial cell density on NiTi surfaces with sub-micron to nanometer roughness
Evidence-based decision-making within the context of globalization: A “Why–What–How” for leaders and managers of health care organizations
Radiolucency below the crown of mandibular horizontal incompletely impacted third molars and acute inflammation in men with diabetes
"Globalized public health.” A transdisciplinary comprehensive framework for analyzing contemporary globalization’s influences on the field of public health
The pathophysiology of bronchiectasis
Amino acid management of Parkinson’s disease: a case study
Evaluation of in-vitro antibiotic susceptibility of different morphological forms of Borrelia burgdorferi
Long-term treatment of bipolar disorder with a radioelectric asymmetric conveyor
Elucidation mechanism of different biological responses to multi-walled carbon nanotubes using four cell lines
- Have an opinion about one of our articles?
We encourage you to write a Letter to the Editor
- Interested in being a peer-reviewer?
Click here to register.
- Display new articles on your site
Use our widget to show articles on your own site
- Applications of gold nanoparticles in cancer nanotechnology
- Fungus-mediated biological synthesis of gold nanoparticles: potential in detection of liver cancer
- Gold nanoparticles: From nanomedicine to nanosensing
- Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases




